Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 16.39
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicine in China. It offers NormalGEN, a type of biological dura repair patch manufactured from animal tissue; GrandNeuro, an artificial dura patch for dura repairing; ThormalGEN, a biological surgical patch manufactured from animal tissue for surgical repairs; DermalGEN, a wound dressing product manufactured from animal tissue for...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Data is available to registered users only
